Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Prevas interim report January - June, all-time-high for the half year

Profitable growth for the quarter and an all-time-high for the half year. April - June 2023 · Net turnover 377.7 MSEK (335.3) · Operating profit EBITA 34.7 MSEK (34.9) · Operating margin EBITA 9.2% (10.4) · Operating profit EBIT 33.0 MSEK (33.6) · Operating margin EBIT 8.7% (10.0) · Profits after tax 25.0 MSEK (28.7) · Earnings per share before dilution 1.92 SEK (2.16) · Earnings per share after dilution 1.90 SEK (2.16) January - June 2023 · Net turnover 772.0 MSEK (650.9) · Operating profit EBITA 94.2 MSEK (79.1) · Operating margin EBITA 12.

Interim report Q2/2023: An exciting and important time ahead

Q2 H1 · Net sales reached SEK 8.8 (9.6) · Net sales reached SEK 21.8 (13.8)million. million. · The operating result totaled SEK · The operating result totaled SEK-11.2 (-15.9) million. -25.5 (-34.0) million. · Earnings per share, basic and · Earnings per share, basic anddiluted, were SEK -0.07 (-0.10). diluted, were SEK -0.16 (-0.22). · Cash flow from operating · Cash flow from operatingactivities totaled SEK -9.5 (-21.5) activities totaled SEK -21.7 (-31.7)

Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)

The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the “Meeting”), to be held on Tuesday, 15 August 2023 at 10.00 at the offices of Mannheimer Swartling Advokatbyrå, Norrlandsgatan 21, Stockholm, Sweden. Registration for the Meeting will begin at 09.30.   The Board of Directors has decided that shareholders shall be able to exercise their voting rights at the Meeting also by postal voting in accordance with the regulations in Sobi’s Articles of Association.   Right to participate and

SmartCraft ASA (SMCRT) – Acquiring Coredination and strengthening Nordic construction software leadership position

18 July 2023: SmartCraft ASA has acquired Coredination AB, a Swedish SaaS solution for construction companies, expanding the value proposition to new customer groups in the construction industry and allowing for increasing cross-sell and upsell to existing customers. “We have a proven history of successful acquisitions, adding product offerings and accelerating revenue and margin development in the acquired companies. This is our 10[th] bolt-on acquisition, and we are confident that the Coredination team and their solution will be a good supplement to the group. They have a modern

Getinge Interim Report April - June 2023: Growth overshadowed by challenges in two product categories

“Getinge’s sales increased organically by 1.3% during the quarter, while the order intake fell by 4.5%,” says Mattias Perjos, President & CEO. “Solving the challenges within Acute Care Therapies is a top priority, and we are starting to see positive effects from the hard work. The CE certificate for our aortic balloon pump was reinstated in mid-July.”Most of the operations in the Business Area Acute Care Therapies performed positively, but quality and supply challenges in the product categories of Cardiac Assist and Cardiopulmonary impacted adjusted EBITA by approximately SEK -400 M, which

Alligo Interim Report 1 Jan-30 June 2023 – Strong quarter and first six months

Second quarter highlights · Revenue increased by 5.0 per cent to MSEK 2,388 (2,275). Organic growth was 2.7 per cent. Gross margin increased to 40.9 per cent (40.5). · Adjusted EBITA increased by 17 per cent to MSEK 201 (172), corresponding to an adjusted EBITA margin of 8.4 per cent (7.6). · Operating profit increased to MSEK 183 (155) and the operating margin was 7.7 per cent (6.8). · Operating profit was charged with items affecting comparability of MSEK -4 (0). · Profit amounted to MSEK 124 (113). · Earnings per share amounted to SEK 2.42 (2.24). · Cash flow from

Fastighets AB Balder Interim report January-June 2023

· Profit from property management attributable to the parent company’s shareholders amounted to SEK 3,099m (2,883), corresponding to an increase per share by 4 % to SEK 2.69 (2.58). · Long term net asset value amounted to SEK 91.12 per share (91.97). · Rental income amounted to SEK 5,838m (5,057). · Profit after tax attributable to the parent company’s shareholders amounted to SEK -918m (8,717) corresponding to SEK -0.80 per share (7.79). Profit from property management for the period amounted to SEK 3,302m (3,167). Profit from property management attributable to the

Interim report 1 January – 30 June 2023

SECOND QUARTER (1 April – 30 June 2023) · Net sales for the quarter amounted to MSEK 110 (53). · Operating profit before depreciation and amortisation (EBITDA) totalled MSEK 69 (25). · Operating profit (EBIT) was MSEK 53 (10). · Profit/loss after tax totalled MSEK 36 (-6) and earnings per share to SEK 0.85 (-0.13). · Operating cash flow was MSEK 60 (67) and cash flow after investments amounted to MSEK -167 (-12). · Production generated 54 GWh (61) of green electricity with an average income of SEK 947 (675)/MWh. · Arise completed the previously announced acquisition

CS MEDICA A/S: Release of 2022/2023 Q3 report, for the period April – June 2023, including an invitation to a live-streamed conference call on 8nd August, at 10 AM CET.

CS MEDICA (”CS MEDICA” or the ”Company”) hereby releases its Q3 report for the period April – June 2023. Highlights of the period will be presented at a live-streamed conference call on Tuesday the 8nd of August at 10 AM CET. The Q3 report is available as an attached document to this press release and on the Company's website (www.cs-medica.com). Below is a summary of the report.Performance highlights · In this third quarter of 2022/2023 (April – June 2023), CS MEDICA delivered net sales of tDKK 673 (1 107) and an order intake of mDKK 8.4 in Q3, which accumulates to mDKK 11,3 year-to-

Q2 2023: Weak underlying market in the Americas and EMEA

Important events during the second quarter · Net sales decreased by 18% (21% adjusted for currency effects) to SEK 144 m (175). · The EBITDA margin amounted to 9% (26) and was burdened by items affecting comparability. Adjusted for these, the EBITDA margin was 17%. · Approval of HEAL9™ in Thailand. Enables further expansion in APAC. · Takeover of distribution of our own brand Probi® in Sweden and entry into Norway with new agreements with pharmacies. · Exclusive distributor of BLIS K12™ and BLIS M18™ ingredients in the US and Canada as of August 1. · New partnership with

Terveystalo Group Half-Year Report January-June 2023: Good profit development across segments in the second quarter of the year

Terveystalo Plc, Half-Year Report 18 July, 2023 at 09:00 EEST This release is a summary of Terveystalo's Half-Year Report 2023. The full release is attached to this stock exchange release and is available on our website at: https://www.terveystalo.com/en/company/investors/reports-and-presentations/ April-June 2023 in brief · Revenue increased by 1.3% year-on-year to EUR 322.4 (318.2) million.The Healthcare Services segment revenue increased by 4.7% and was EUR 234.7 (224.1) million.Portfolio Businesses revenue decreased by 7.7% and was EUR 68.6 (74.3) million.The revenue

Orexo Q2 2023 Interim Report

The patent win critical enabler for future growth Q2 2023 highlights›     Total net revenues of SEK 157.7 m (147.8)›     EBITDA of SEK 5.6 m (-32.5), EBITDA excluding legal costs and costs for non-­repeating ­clinical trials, SEK 30.3 m (11.4) ›     Net earnings of SEK -12.6 m (-35.8)›     US Pharma segment (ZUBSOLV® US) net revenues of SEK 145.4 m (139.6), in local currency USD 13.8 m (14.2), US Pharma EBIT of SEK 71.2 m (77.2)›     Cash flow from operating activities of SEK -12.7 m (14.5), cash and invested funds of SEK 251.1 m (467.7)›     Earnings per share before and

REPORT ON THE SECOND QUARTER 2023

CONTINUED SOLID EARNINGS AND RECORD-HIGH OPERATING CASH FLOWSECOND QUARTER 2023 · Net sales were SEK 8,329 m (8,498); a decrease of -2%, of which -10% was organic growth. · Operating profit (EBITA) before items affecting comparability was SEK 1,177 m (1,330), corresponding to a margin of 14.1% (15.7%). · Items affecting comparability were SEK -35 m (-14). · Operating profit (EBITA) was SEK 1,143 m (1,316), corresponding to a margin of 13.7% (15.5%). · Operating profit (EBIT) was SEK 985 m (1,166), corresponding to a margin of 11.8% (13.7%). · Profit (loss) for the

Bactiguard Holding AB’s Interim Report Q2 2023

Strategy of bolstering Licensing and US go-to-market stays firmSecond Quarter 2023 (April-June) · Total revenues amounted to SEK 51.2 (59.9) million, a decrease of 15 %. Net sales amounted to SEK 44.2 (51.8) million. Adjusted for the currency effect, net sales decreased by 19 %. · Operating loss amounted to SEK 67.8 (14.8) million, an increase of SEK 53.0 million, SEK 42 million of the EBITDA loss correspond to a necessary adjustment pertaining mainly to a write-down of inventory, a reservation of receivables and related projects, and an accrual for costs related to restructuring.

Sobi publishes Q2 2023 report: Growth and pipeline expansion

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2023Second quarter 2023 · Total revenue increased 26 per cent, +16 per cent at constant exchange rates, (CER)i, to SEK 4,872 M (3,876) · Haematology revenue increased 18 per cent at CER to SEK 3,430 M (2,688). Driven by Doptelet® +74 per cent at CER and the launch of Aspaveli®/Empaveli® SEK 144 M · Immunology revenue increased 29 per cent at CER to SEK 1,179 M (847). Driven by Gamifant® +73 per cent at CER and Kineret® +12 per cent at CER · Adjusted EBITAi margin expanded by 1

DNB Markets - IAR Systems: fair value cut to SEK120-200

Amid 1) a hiccup in its turnaround; 2) a shift in the investor base; and 3) low liquidity in the shares, IAR Systems’ share price is back at 2015 levels. We have educed our 2023–2024e EPS by 33–20% to factor in slower organic growth (with high drop-through). Although 2023 seems to be a difficult year, we appreciate the combination of profitable growth, being net cash positive, defensive elements from c40% recurring revenues, and optionality from its embedded security offering. We note insiders have accumulated shares above current share-price levels recently. We have lowered our fair value to

Kemira Oyj’s Half-year Financial Report 2023: Strong performance in Industry & Water compensated for soft pulp and paper market

Kemira Oyj, Half-year Report, July 18, 2023 at 8.30 am (EEST)Kemira Oyj’s Half-year Financial Report 2023: Strong performance in Industry & Water compensated for soft pulp and paper marketThis is a summary of the January - June 2023 Half-year Financial Report. The complete report with tables is attached to this release and available at kemira.com/investors . Second quarter:   •    Revenue decreased by 2% to EUR 840.1 million (861.4). Revenue in local currencies, excluding acquisitions and divestments, increased by 0.5% as revenue growth in

Strong growth and margin improvement in all business areas

April - June ·Order intake was flat organically, with good development in business areas FoodTech and Data Center Technologies (DCT), and a stable development in AirTech. ·Net sales increased +27% organically, mainly driven by a very strong growth in DCT and the battery sub-segment in AirTech. FoodTech had a strong development in Americas, in both Climate and Digital Solutions, that was offset by a weak development in EMEA and APAC. ·The strong improvement in the adj. EBITA margin was mainly related to increased net sales in DCT and AirTech, as well as efficiency

Panoro Energy – Start-up of Gas Lift Compressor on BW Adolo FPSO

Oslo, 18 July 2023 – Panoro Energy ASA (“Panoro” or the “Company”) notes the operator of the Dussafu Marin Permit offshore Gabon has today announced start-up of the new gas lift compressor on the BW Adolo FPSO following recent commissioning and gradual ramp up of gas lift capacity. The gas lift compressor will support production from all six existing wells at the Tortue field and once fully operational is expected to add approximately 3,000 bopd of gross production. Panoro hold a 17.5 percent working interest in the Dussafu Marin Permit. Enquiries Qazi Qadeer, Chief Financial

Munters initiates strategic review of equipment offering in FoodTech

Munters has decided to accelerate the focus on digital growth in FoodTech. Therefore, a strategic review of the equipment offering has been initiated. The strategic review includes exploring different options and may result in partial divestments, although no such decisions have yet been taken.Munters continuously evaluates the strategic direction as well as offering within the company’s three business areas, AirTech, Data Center Technologies and FoodTech, to achieve increased long-term value creation. Therefore, Munters has decided to accelerate the focus on digital growth (software, IoT,

Interim report for the second quarter and the first half of 2023

Increase in orders received and higher profit.“NCC had a positive quarter with good orders received and higher operating profit. There is favorable demand in many segments”, says Tomas Carlsson, CEO NCC.  · Good orders received and strong order backlog in all business areas · Systematic improvement in operating profit for Infrastructure · Construction operations notes stable sales, but are impacted by lower margins · Industry reported higher year-on-year operating profit · Cash flow is seasonally negative Second quarter of 2023 · Orders received amounted to SEK 14,

Kemira Oyj: Petri Castrén appointed as Interim President & CEO

Kemira Oyj, Stock Exchange Release, July 18, 2023 at 8.05 am (EEST)Kemira Oyj: Petri Castrén appointed as Interim President & CEO As announced earlier today, Kemira’s Board of Directors and President & CEO Jari Rosendal have agreed that Jari Rosendal will leave his position as the President & CEO latest during 2024. Kemira’s Board has decided to initiate the search for his successor. Kemira announced on July 11, 2023 that Jari Rosendal is on sick leave for the time being. Kemira’s Board of Directors has appointed Petri Castrén as Interim President & CEO as of July 18, 2023. He will be

Aker ASA: Half-Year and Second Quarter Results 2023 – Net Asset Value of NOK 57.2 billion

The Net Asset Value ("NAV") of Aker ASA and holding companies ("Aker") was NOK 57.2 billion at the end of the second quarter 2023, down NOK 2.5 billion from NOK 59.7 billion at the end of the first quarter, of which NOK 1.1 billion was dividends paid. While the Net Asset Value (NAV) was down 2.3 percent, adjusted for dividends paid, most of the Aker portfolio experienced strong operational performance during the second quarter and continues to pursue global megatrends.The per-share NAV amounted to NOK 770 at the end of the quarter. This compares to NOK 803 at the end of the first quarter

Camurus’ Interim Report Second Quarter 2023

“Outstanding second quarter with strong revenue growth, record result, FDA approval and positive phase 3 results” Second quarter summary April - June · Total revenues amounted to SEK 674 (227) million, an increase of 197% (185% at CER[1]), whereof product sales were SEK 305 (225) million, an increase of 36% (32% at CER[1]) · Compared to previous quarter, product sales increased 8% · Operating result was SEK 376 (7) million, an increase of SEK 369 million · Cash position at the end of the quarter was SEK 654 (428) million, an increase of SEK 226 million (53%) · Number

There are no items matching the current filter
There are no more items matching the current filter
Back to top